Biotech venture funding has been on a tear for the past couple of years, and corporate investors in the space are doing their part to boost the totals.

Here at Crunchbase, we’ve put together an index of the largest pharma and biotech companies active in startup investment, along with their in-house venture arms. For the second year in a row, we’re tallying their venture investments by round count and dollar totals.

The broad finding? Corporate biotech investors sharply increased the sums put into startup rounds they led in 2018. Overall, they also participated in rounds that were valued at nearly twice year-ago levels.

These aren’t small sums either. In all of 2018, corporate venture investors participated in rounds valued at $8 billion. Rounds with a corporate bio VC as lead investor, meanwhile, totaled around $1.7 billion.

Below, we drill down into a bit more detail, looking at funding totals for the past five years, largest rounds and most active investors.

[Read More]

LEAVE A REPLY

Please enter your comment!
Please enter your name here